Adaptive Biotechnologies Corp
$ 16.05
4.29%
24 Feb - close price
- Market Cap 2,366,665,000 USD
- Current Price $ 16.05
- High / Low $ 16.21 / 15.39
- Stock P/E N/A
- Book Value 1.42
- EPS -0.39
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.28 %
- 52 Week High 20.76
- 52 Week Low 6.25
About
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Analyst Target Price
$20.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-11-06 | 2025-08-05 | 2025-05-01 | 2025-02-11 | 2024-11-07 | 2024-08-01 | 2024-05-07 | 2024-02-14 | 2023-11-09 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.09 | 0.06 | -0.17 | -0.2 | -0.23 | -0.22 | -0.31 | -0.33 | -0.3 | -0.35 | -0.33 | -0.4 |
| Estimated EPS | -0.18 | -0.18 | -0.24 | -0.31 | -0.24 | -0.27 | -0.33 | -0.34 | -0.33 | -0.34 | -0.35 | -0.38 |
| Surprise | 0.09 | 0.24 | 0.07 | 0.11 | 0.01 | 0.05 | 0.02 | 0.01 | 0.03 | -0.01 | 0.02 | -0.02 |
| Surprise Percentage | 50% | 133.3333% | 29.1667% | 35.4839% | 4.1667% | 18.5185% | 6.0606% | 2.9412% | 9.0909% | -2.9412% | 5.7143% | -5.2632% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1746 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADPT
2026-02-21 11:41:26
TD Cowen has upgraded Adaptive Biotechnologies (ADPT) price target to $21 from $20, maintaining a Buy rating, citing a Q4 beat and improved outlook driven by community adoption and EMR integrations. BTIG and JPMorgan also increased their price targets for ADPT, maintaining Buy and Overweight ratings respectively, following strong Q4 earnings. Adaptive Biotechnologies anticipates FY26 MRD business revenue between $255 million and $265 million.
2026-02-21 06:01:00
TD Cowen has upgraded Adaptive Biotechnologies Corporation (ADPT)'s price target to $21 from $20, maintaining a Buy rating after a strong Q4 performance and improved outlook. BTIG and JPMorgan also increased their price targets for ADPT, citing robust Q4 results and the company's leading position in specialty labs. ADPT anticipates FY26 MRD business revenue to be between $255 million and $265 million.
2026-02-09 10:27:42
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 42,788 shares of ADPT stock for approximately $799,104 across February 2nd and 3rd, 2026. These sales were executed near the company's 52-week high, following an impressive 114.91% return over the past year for ADPT shares, currently trading at $17.30. The company reported strong financial results for 2025, with revenue increases and strategic partnerships, leading Piper Sandler to reiterate an Overweight rating.
2026-02-08 04:59:00
Adaptive Biotechnologies (NASDAQ:ADPT) exceeded analyst expectations for its full-year results, with revenues of US$277m and statutory losses of US$0.39 per share, both better than anticipated. Following these results, analysts have updated their 2026 forecasts, predicting revenues of US$277.2m and a 28% increase in losses to US$0.49 per share, marking a noticeable increase in sentiment despite no change to the consensus price target. The company's projected revenue growth of 0.09% annually until 2026 is significantly lower than its historical 12% p.a. over the last five years and also slower than its industry peers.
2026-02-06 22:58:25
Adaptive Biotechnologies (NASDAQ:ADPT) reported strong financial results for Q4 and full-year 2025, with total revenue growing 55% year-over-year. The company's MRD business achieved profitability ahead of expectations, with revenue up 46%, driven by increased clonoSEQ test volumes and ASP expansion. Adaptive also highlighted progress in its Immune Medicine business through data partnerships and strategic focus on AI modeling, projecting positive adjusted EBITDA and free cash flow for the entire company by the end of 2026.
2026-02-06 11:59:54
BTIG has raised its price target for Adeptus Biotechnologies (NASDAQ:ADPT) to $22.00 from $21.00, maintaining a Buy rating. This adjustment follows the company's robust growth in its Minimal Residual Disease (MRD) business, which saw a 54% year-over-year increase in Q4 2025 and 46% for the full year. The company also exceeded analyst expectations for Q4 2025 earnings and revenue, reporting an EPS of -$0.09 and revenue of $71.7 million.
